NCT06494527View on ClinicalTrials.gov

A Phase 1 Study to Evaluate the Safety/Tolerability, PK/PD of RG002C0106 Injection in Healthy Adults

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 9, 2024

Primary Completion Date

October 20, 2025

Study Completion Date

December 31, 2025

Conditions

Safety Issues

Interventions

DRUG

RG002C0106

RG002C0106 is a siRNA drug targeting complement C3 to silence the related gene through the RNA interfering mechanism and inhibit the expression of C3 protein.

All Listed Sponsors

lead

Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd.

INDUSTRY

NCT06494527 - A Phase 1 Study to Evaluate the Safety/Tolerability, PK/PD of RG002C0106 Injection in Healthy Adults | Biotech Hunter | Biotech Hunter